colorectal cancer
Conditions
Interventions
None listed
Sponsors
Yokohama City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient who plans the medication of the following anticancer agents as colorectal cancer chemotherapy CPT-11 or oxaliplatin 2. The patient whom an anticancer agent is not given to or an anticancer agent of low emetic risk has been given to in the past 3. The planned patient who gives the following antiemetic drugs in the time giving an anticancer agent day 1 palonosetron (0.75mg) i.v. dexamethasone (9.9mg) i.v. day 2, 3 dexamethasone (8mg) p.o. 4. Age at the time of the registration is a patient 20 years or older 5. The patient who can fill in a diary with a symptom exactly 6. Given written informed consent
Exclusion criteria
Exclusion criteria: 1. The patient who experienced nausea or vomiting within 24 hours before giving an anticancer agent 2. Any other inadequacy for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate during 24 to 120 hours (delay phase) after an anticancer agent dosage start | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Complete response rate during 0 to 24 hours (acute phase) and 0 to 120 hours (all phase ) after an anticancer agent dosage start 2. Complete control rate during acute phase and delay phase and all phase after an anticancer agent dosage start 3. Grade of nausea during acute phase and delay phase and all phase after an anticancer agent dosage start | — |
Countries
Japan
Contacts
Public ContactKazuki Watanabe
Yokohama City University Hospital Department of gastroenterological surgery
Outcome results
None listed